Breast technology developer Biofield has terminated discussions of a potential merger or acquisition with Bay Point Group.
The companies had written a letter of intent regarding a potential merger on June 28, but terminated the letter due to a mutual understanding that a merger would not be in the best interests of the parties at this time, according to the Atlanta-based firm. Biofield said it would continue to seek possibilities for expanding its women's healthcare product line.
By AuntMinnie.com staff writersAugust 11, 2005
Related Reading
FDA rejects Biofield data, July 25, 2005
FDA denies Biofield regulatory request, March 9, 2005
Biofield makes regulatory progress on BDS, November 16, 2004
Biofield nets African distribution deal, December 7, 2001
Biofield to try again with FDA, September 18, 2001
Copyright © 2005 AuntMinnie.com
